Heron Therapeutics (HRTX) said Tuesday it reached a settlement agreement with Viatris' (VTRS) Mylan Pharmaceuticals to resolve patent litigation over the Cinvanti and Aponvie injectable emulsions.
Under the deal, Heron granted Mylan a license to market generic versions of Cinvanti and Aponvie in the US beginning June 1, 2032.
In connection with the settlement, Heron and Mylan will ask the US District Court for the District of Delaware to dismiss the pending litigations, Heron said.
The company said it initiated the litigations in response to what it described as Mylan's abbreviated new drug applications seeking the US Food and Drug Administration's approval of generic Cinvanti and Aponvie versions before the expiration of the Heron patents in 2035.
Heron shares rose nearly 14% in recent trading.
Price: 2.43, Change: +0.30, Percent Change: +13.85
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。